121 Bio
2013
FOUNDED
OOB
STATUS
Out of Business
LATEST DEAL TYPE
Description
Developer of a suite of innovative research tools designed for modification of proteins and cells and innovative cellular immunotherapies. The company's research tools will help drive fundamental new discoveries in protein structure/function and through systematic and deliberate modification of proteins, providing a platform for development of protein-based drugs with enhanced performance.
Primary Industry
Biotechnology
Other Industries
Other Healthcare
Primary Office
- 700 Main Street
- Cambridge, MA 02139
- United States
+1 (617) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore 121 Bio’s full profile, request a free trial.
121 Bio Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 01-May-2017 | Completed | Out of Business | |||
| 1. Early Stage VC (Series A) | 01-Jan-2014 | Completed | Startup |
121 Bio Executive Team (4)
121 Bio Board Members (4)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Hidde Ploegh Ph.D | Self | Co-Founder & Board Member | 000 0000 | |
| James Gorman Ph.D | Self | Co-Founder, Chief Executive Officer, CSO and Board Member | 000 0000 |
2 Former Board Members
You’re viewing 2 of 4 board members. Get the full list »